Navigation Links
Amgen's Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
Date:7/30/2013

THOUSAND OAKS, Calif., July 30, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2013.  Key results for the quarter include:

  • Total revenues increased 5 percent to $4,679 million, with 9 percent product sales growth driven by Enbrel® (etanercept), Neulasta® (pegfilgrastim), XGEVA® (denosumab), and Prolia® (denosumab).  Product sales included a positive adjustment of $185 million to previous estimates for managed Medicaid rebates based on recent claims experience.  Other revenues were lower by $193 million as a result of a payment from Takeda recognized in the second quarter of 2012.
  • Adjusted EPS grew 3 percent to $1.89, with higher revenues and a lower tax rate partially offset by increased Research & Development (R&D) investment.  Adjusted net income increased 1 percent to $1,444 million.
  • GAAP EPS were $1.65 compared to $1.61 and GAAP net income was $1,258 million compared to $1,266 million.
  • The Company generated approximately $1.4 billion of free cash flow.
  • "We saw solid product trends during the second quarter and are carrying good momentum into the second half," said Robert A. Bradway, chairman and chief executive officer at Amgen. "We continue to make excellent progress with our pipeline of innovative molecules and look forward to multiple data readouts in 2014, including pivotal Phase 3 data for our cholesterol-lowering agent, AMG 145, in the first quarter."Year-over-Year$Millions, except EPS and percentagesQ2 '13Q2 '12YOY ΔTotal Revenues$4,679$4,4775%Adjusted Net Income1,4441,4331%Adjusted EPS1.891.833%GAAP Net Income1,2581,266(1%)GAAP EPS$1.65$1.612%References in this release to "adjusted" measures, measures presented "on an adjusted basis" or to free cash flow refer
    '/>"/>

    SOURCE Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Covance Reports Second Quarter Net Revenue of $592 Million, Pro Forma EPS of $0.78 and Record Adjusted Net Orders of $776 Million
    2. Oncology remains most restrictive specialty for second year
    3. China Biologic Products to Report Second Quarter 2013 Financial Results
    4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
    5. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
    6. Webcast Alert: Isis Pharmaceuticals Second Quarter 2013 Financial Results Conference Call
    7. VirtualScopics Schedules Second Quarter 2013 Earnings Announcement
    8. Luminex Corporation Reports Second Quarter 2013 Results
    9. Endo to Announce Second Quarter 2013 Financial Results on August 6, 2013
    10. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
    11. PDI, Inc. to Hold Second Quarter 2013 Financial Results Conference Call on Monday, August 5, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/18/2014)... MIAMI , Nov. 18, 2014 ... increased median overall survival and progression free survival at ... treated with Toca 511 & Toca FC, compared to ... aggressive form of primary brain cancer. The data were delivered ... Annual Scientific Meeting and Education Day of the Society ...
    (Date:11/17/2014)... , Nov. 17, 2014 Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that ... and Development, will participate in a live Google Hangout ... (CIRM) discussing the latest progress in stem cell-based therapies ... Google Hangout session is scheduled for Tuesday, November 18, ...
    (Date:11/17/2014)... , Nov. 17, 2014  Inovio Pharmaceuticals, Inc. ... and Roche have terminated their 2013 collaboration, option, and ... prostate cancer, as well as their research collaboration in ... the right to license the product to other parties, ... advance INO-5150 into a phase I clinical trial in ...
    Breaking Medicine Technology:Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 2Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 3Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 4Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 5Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury 2Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 2Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 3Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 4Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 5
    (Date:11/18/2014)... Concord, Massachusetts (PRWEB) November 18, 2014 ... focused on the development and commercialization of specialized ... Patent Office has granted Cristcot a patent for ... suppository applicator, Sephure®. , The patent ... and the property rights have been assigned to ...
    (Date:11/18/2014)... HealthDay Reporter MONDAY, ... abnormal heartbeat known as atrial fibrillation who take common ... blood clots, according to a new study. That ... blood thinner along with one of these nonsteroidal anti-inflammatory ... (Aleve) and celecoxib (Celebrex). "If you add ...
    (Date:11/18/2014)... Recently, BellasDress has announced the launch of ... workers and using comfortable fabrics, the new styles of prom ... variety of wonderful holiday gifts in a variety of colors ... prom dresses, and they are created by top designers,” said ... absolutely great addition to our sales team and more than ...
    (Date:11/18/2014)... (PRWEB) November 18, 2014 Sometimes at ... situations with print devices like unforeseen error messages or ... don't have time to find another printer and they ... The IT department is likely tied up with other ... , That’s where Electronic Systems, Inc. (ESI) ...
    (Date:11/18/2014)... Tara Haelle HealthDay Reporter ... who experience a severe abusive head trauma before the age ... a new study. In addition, among those who ... half, the study found. Abusive head trauma includes shaken ... and suffers head injuries, according to background information in the ...
    Breaking Medicine News(10 mins):Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Some Painkillers Tied to Bleeding Risk in Those With Abnormal Heartbeat 2Health News:85 New Models Of White Prom Dresses From BellasDress.com Online For Sale 2Health News:Electronic Systems, providing Managed Print Services (MPS) in Virginia & Outer Banks North Carolina 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 3Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 4
    ... , , SEATTLE, July 29 ... that it was notified by the European Medicines Agency ("EMEA") that ... ("MAA") through the EMEA,s centralized procedure. The centralized review process provides ... is conducted by the EMEA on behalf of all European Union ...
    ... , , , ... called Indiana Drug Card, is being launched today. The program, which ... pharmacy discounts on prescription drugs. This program has no restrictions on ... applications to fill out. Indiana Drug Card is accepted at over ...
    ... risk rises 75 percent when device use begins before age ... -- The International Agency for Research on Cancer on Tuesday ... "carcinogenic to humans," according to a new report. , Previously, ... carcinogenic, so the move puts the devices a notch higher ...
    ... Finding time to treat the "you" in yourself is important to maintaining ... how you can do just that with the right simple snack. , ... , http://inr.mediaseed.tv/oneClip_C/?feed=LRP2yXtJhkA_O5oRbn5PG4L4KgGq7sMi , , ... free and unrestricted use at http://www.mediaseed.tv . ...
    ... NEW YORK, JULY 28 The American Society of ... the 2009 updated Interventional Pain Management (IPM) guidelines. , ... stated that, "The purpose of the IPM guidelines is to ... chronic or persistent pain, and provide information about the scientific ...
    ... , DETROIT, July 28 Caraco ... sales of $48.1 million in the first quarter of Fiscal 2010, ... period of Fiscal 2009. The reduction in sales was primarily due ... as compared to the corresponding period of Fiscal 2009. Sales of ...
    Cached Medicine News:Health News:Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 2Health News:Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 3Health News:Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 4Health News:Indiana Drug Card to Provide Free Drug Cards to Residents 2Health News:Tanning Beds Get Highest Carcinogen Rating 2Health News:Tanning Beds Get Highest Carcinogen Rating 3Health News:New Interventional Pain Management Guidelines Released by the American Society of Interventional Pain Physicians 2Health News:New Interventional Pain Management Guidelines Released by the American Society of Interventional Pain Physicians 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 5Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 6Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 7
    ... The table-mounted knee retractor ... for total knee arthroplasty ... open-frame design allows for ... knee during the procedure. ...
    ... every general surgery need. No matter the ... GO450/GO400 Omni-Flex™ General Retractor Systems give you ... best possible exposure in the simplest way ... the hinged extension arm, the GO450 provides ...
    ... general surgery need. No matter the size ... Omni-Flex General Retractor Systems give you the ... possible., ,With large and small frame arms, ... GO550 provides comprehensive flexibility and completely scalable ...
    Specifically designed to address the requirements of spine specialists performing vertebroplasty or kyphoplasty procedures....
    Medicine Products: